This stock is no longer traded. It was delisted on July 9, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Lipella Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of new therapies for individuals suffering from debilitating urological disorders. The primary function of Lipella Pharmaceuticals is to create innovative treatment options that target unmet medical needs, particularly those related to bladder conditions. This involves drug delivery technologies and formulations designed to improve the efficacy and safety profiles of existing therapies. Lipella operates within the pharmaceutical and healthcare sectors, directly impacting patients and medical professionals seeking advanced solutions in urology. The company's research and development efforts aim at expanding treatment options to enhance the quality of life for patients who have limited therapeutic alternatives. In the financial market, Lipella Pharmaceuticals occupies a niche space within the biotech industry, offering potential growth pathways as it progresses through clinical trials and regulatory approvals. Its developments are closely monitored by stakeholders interested in medical innovation and potential breakthroughs in urological medicine.
Website7800 Susquehanna St.
Pittsburgh, PA, 15208
United States
Summary of Jun 23's posts. Generated by AI.
Summary of Feb 11's posts. Generated by AI.
Summary of Feb 12's posts. Generated by AI.
Investors talking about LIPO also mention these. Each card shows that asset’s own numbers for the past 24 hours.